Oncology Clinical Trials and Research

At the Bri­an Moran Can­cer Insti­tute, research and inno­va­tion are part of how we care for our patients every day. Our goal is to bring the best in ongo­ing can­cer research to our com­mu­ni­ty, giv­ing you access to promis­ing new treat­ments close to home. Through clin­i­cal tri­als, patients can receive advanced ther­a­pies that may improve out­comes, enhance qual­i­ty of life, and shape the future of can­cer care.

Why clin­i­cal tri­als matter

Clin­i­cal tri­als are the bridge between today’s stan­dard treat­ments and tomorrow’s break­throughs. Every approved can­cer ther­a­py began in a research study. By par­tic­i­pat­ing in a clin­i­cal tri­al, you can gain access to new treat­ments while help­ing researchers and physi­cians learn more about how to pre­vent, detect, and treat can­cer more effectively.

Our physi­cians at the Bri­an Moran Can­cer Insti­tute lead research in gen­i­touri­nary, gas­troin­testi­nal, tho­racic, and breast can­cers. By part­ner­ing with com­pa­nies devel­op­ing new can­cer ther­a­pies and using advanced tools like bio­mark­er test­ing and genom­ic sequenc­ing, we match patients with clin­i­cal tri­als that best fit their indi­vid­ual disease.

Our approach to research

We design and con­duct research that puts patients first. That means:

  • Access to inno­va­tion: We attempt to select and offer stud­ies with the most promis­ing pre-clin­i­cal and ear­ly-phase clin­i­cal data. 
  • Per­son­al­ized match­ing: We use bio­mark­ers such as genom­ic test­ing to iden­ti­fy which stud­ies may offer the great­est ben­e­fit for your spe­cif­ic can­cer type and stage.
  • Mul­ti­dis­ci­pli­nary exper­tise: Every tri­al par­tic­i­pant is cared for by a team that includes oncol­o­gists, research coor­di­na­tors, nurse nav­i­ga­tors, and phar­ma­cists who mon­i­tor safe­ty, results, and over­all well-being.
  • Focus on qual­i­ty of life: Tri­als are care­ful­ly select­ed to bal­ance inno­va­tion with com­fort and safe­ty. Par­tic­i­pa­tion is always vol­un­tary, and your care team is here to sup­port you at every step.

Cur­rent clin­i­cal trials

The Bri­an Moran Can­cer Insti­tute offers a grow­ing list of open clin­i­cal tri­als across mul­ti­ple can­cer types and treat­ment stages.

Cur­rent stud­ies include:

  • NCT07195695 — Bri­an Myre, MD — A ran­dom­ized, con­trolled, mul­ti-cen­ter tri­al eval­u­at­ing zonger­tinib as an adju­vant monother­a­py com­pared with stan­dard of care in patients with ear­ly-stage, resectable non-small cell lung can­cer (Stage II-IIIB) har­bor­ing tyro­sine kinase domain acti­vat­ing HER2 mutations
  • NCT07225946 — Bri­an Myre, MD — A Phase 3 Ran­dom­ized, Open-label Study of JNJ-78278343, a T Cell-redi­rect­ing agent tar­get­ing Human Kallikrein 2, with Doc­etax­el Ver­sus Doc­etax­el for Metasta­t­ic Cas­tra­tion-Resis­tant Prostate Cancer
  • NCT06312137 — Bri­an Myre, MD — Phase 3 Ran­dom­ized Open-Label Study of Adju­vant Pem­brolizum­ab With or With­out MK-2870 in Par­tic­i­pants With Resectable Stage II to IIIB (N2) NSCLC not Achiev­ing pCR After Receiv­ing Neoad­ju­vant Pem­brolizum­ab With Plat­inum-based Dou­blet Chemother­a­py Fol­lowed by Surgery
  • NCT07144280 — Bri­an Myre, MD — A Ran­dom­ized, Phase 3, Open-Label Study to Eval­u­ate PF-08046054/S­GN­PDL1V Ver­sus Doc­etax­el in Adult Par­tic­i­pants With Pre­vi­ous­ly-Treat­ed Pro­grammed Cell Death Lig­and 1 (PD-L1) Pos­i­tive Non-Small-Cell Lung Can­cer (NSCLC)
  • NCT06533644 — Bri­an Myre, MD — A Phase 2a Mul­ti­cen­ter Dose Esca­la­tion and Dose Opti­miza­tion Study of SYNC‑T Ther­a­py SV-102 for Patients with Metasta­t­ic Cas­tra­tion-Resis­tant Prostate Can­cer (mCR­PC)
  • NCT06629779 — Amit Patel, MD — A Phase 3, Ran­dom­ized, Dou­ble-Blind, Place­bo Con­trolled Study of PF-06821497 (Mevrome­to­stat) with Enza­lu­tamide in Metasta­t­ic Cas­tra­tion Resis­tant Prostate Cancer
  • NCT06551324 — Amit Patel, MD — A Phase 3, Ran­dom­ized, Open-Label Study of PF-06821497 (Mevrome­to­stat) in Com­bi­na­tion with Enza­lu­tamide Com­pared with Enza­lu­tamide or Doc­etax­el in Par­tic­i­pants with Metasta­t­ic Cas­tra­tion Resis­tant Prostate Can­cer Pre­vi­ous­ly Treat­ed with Abi­raterone Acetate (MEVPRO‑1) 
  • NCT06510374 — Amit Patel, MD — A Phase 3b, Ran­domised, Con­trolled Tri­al of Nad­o­fara­gene Firade­n­ovec vs. Obser­va­tion in Sub­jects with Inter­me­di­ate Risk (IR) Non-Mus­cle Inva­sive Blad­der Can­cer (NMIBC)
  • NCT06545955 — Amit Patel, MD — A phase 2, ran­domised, mul­ti-cen­tre, open-label tri­al to eval­u­ate the safe­ty and effi­ca­cy of intrav­es­i­cal nad­o­fara­gene firade­n­ovec alone or in com­bi­na­tion with chemother­a­py (gem­c­itabine and doc­etax­el) or immunother­a­py (pem­brolizum­ab) in sub­jects with high-grade Bacil­lus Cal­mette-Guerin (BCG) unre­spon­sive non-mus­cle inva­sive blad­der can­cer (NMIBC)
  • NCT06995677 — Amit Patel, MD — A Phase 2 Mul­ti­cen­ter, Open-Label Study Eval­u­at­ing the Effi­ca­cy and Safe­ty of TYRA-300 in Par­tic­i­pants with FGFR3 Altered Low Grade, Inter­me­di­ate Risk Non-Mus­cle Inva­sive Blad­der Can­cer (SURF302)
  • NCT07174336 — Daniel Frank, MD — A Phase 3, Ran­dom­ized, Dou­ble-blind, Place­bo-con­trolled Study of LY4064809 Com­bined with a CDK4/6 inhibitor and Endocrine Ther­a­py in Adults with HR+, HER2- Advanced Breast Can­cer with a PIK3CA Muta­tion who received no pri­or treat­ment for Advanced Breast Can­cer (PIKALO‑2)
  • NCT06111235 — Ranko Mio­ci­novic, MD — A Phase 3, Ran­dom­ized Study of Adju­vant Cre­tosti­mo­gene Grenade­norepvec ver­sus Obser­va­tion for the Treat­ment of Inter­me­di­ate Risk Non-Mus­cle Inva­sive Blad­der Can­cer (IR-NMIBC) Fol­low­ing Transurethral Resec­tion of Blad­der Tumor (TURBT) 
  • NCT04165317 — Ranko Mio­ci­novic, MD — A Phase 3, Multi­na­tion­al, Ran­dom­ized, Open-Label, Three Par­al­lel-Arm Study of PF-06801591, an Anti-PD‑1 Anti­body, in Com­bi­na­tion With Bacil­lus Cal­mette-Guerin (BCG Induc­tion With or With­out BCG Main­te­nance) Ver­sus BCG (Induc­tion and Main­te­nance) in Par­tic­i­pants With High-Risk, BCG-Naïve Non-Mus­cle Inva­sive Blad­der Can­cer or PF-06801591 as a Sin­gle Agent in Par­tic­i­pants With BCG-Unre­spon­sive NMIBC
  • NCT06567743 — Ranko Mio­ci­novic, MD — A Phase 2, Mul­ti-Arm, Mul­ti-Cohort, Open-Label Study to Eval­u­ate the Safe­ty and Effi­ca­cy of Cre­tosti­mo­gene Grenade­norepvec in Par­tic­i­pants With High-Risk Non-Mus­cle-Inva­sive Blad­der Can­cer (NMIBC)
  • NCT04972097 — Ranko Mio­ci­novic, MD — Piv­otal Study of the NanoKnife Sys­tem for Abla­tion of Prostate Tis­sue in an Inter­me­di­ate-Risk Patient Population
  • NCT05468489 — Nafisa Burhani, MD — A Ran­dom­ized, Open-label Study of HLX10 plus Chemother­a­py (Car­bo­platin-Etopo­side) in com­par­i­son with Ate­zolizum­ab plus Chemother­a­py in Pre­vi­ous­ly Untreat­ed US Patients with Exten­sive Stage Small Cell Lung Can­cer (ES-SCLC) 
  • NCT04961996 — Nafisa Burhani, MD — A Phase III, Ran­dom­ized open-label mul­ti­cen­ter study eval­u­at­ing the effi­ca­cy and safe­ty of adju­vant Giredestrant com­pared with physi­cians choice of adju­vant endocrine monother­a­py in patients with Estro­gen recep­tor pos­i­tive, HER2 neg­a­tive ear­ly breast cancer
  • NCT06816121 — Nafisa Burhani, MD — Iden­ti­fi­ca­tion and Val­i­da­tion of Blood-Based Bio­mark­ers for Ear­ly Detec­tion of Asymp­to­matic Lung Can­cer in High-Risk Heavy Smokers
  • NCT05161195 — Nafisa Burhani, MD — A Post-tri­al Access Roll-over Study to Allow Access to Ribo­ci­clib (LEE011) for Patients Who Are on Ribo­ci­clib Treat­ment in Novar­tis-spon­sored Study
  • NCT02513394 — Nafisa Burhani, MD — A ran­dom­ized phase III tri­al of Pal­bo­ci­clib with stan­dard adju­vant endocrine ther­a­py ver­sus stan­dard adju­vant endocrine ther­a­py alone for hor­mone recep­tor pos­i­tive (HR+) / human epi­der­mal growth fac­tor recep­tor 2 (HER2)-negative ear­ly breast cancer
  • NCT06246110 — Nafisa Burhani, MD — A Phase 2 Study of EIK1001 in Com­bi­na­tion with Pem­brolizum­ab and Chemother­a­py in Patients with Stage 4 Non-Small Cell Lung Cancer

If you don’t see a study list­ed for your can­cer type, our research team can review your med­ical infor­ma­tion to see if you may qual­i­fy for a study open­ing soon.

What to expect when you join a trial

Par­tic­i­pat­ing in a clin­i­cal tri­al fol­lows the same high stan­dard of care you receive in any oth­er part of your treat­ment. Before join­ing, your team will explain the study pur­pose, pos­si­ble ben­e­fits, and poten­tial side effects so you can make an informed deci­sion. You’ll have ongo­ing appoint­ments, mon­i­tor­ing, and direct com­mu­ni­ca­tion with your care team through­out the process.

You can leave a clin­i­cal tri­al at any time for any rea­son, and your care will con­tin­ue unin­ter­rupt­ed with your cur­rent oncol­o­gy team.

How to get started

If you’re inter­est­ed in learn­ing more about clin­i­cal tri­als or won­der­ing if one may be right for you, start by talk­ing with your oncologist.

Call us at 630−545−7760 or speak with your nurse nav­i­ga­tor to learn more about avail­able clin­i­cal tri­als and research opportunities.